Name

659032

Description

659032 is the third genomics-derived small-molecule drug coming from a collaboration between Human Genome Sciences and GlaxoSmithKline to enter clinical development. 659032 is a second lipoprotein-associated phospholipase A2(Lp-PLA2) inhibitor.

Brands

No brand information found.